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Abstract
BACKGROUND: The effect of renal replacement therapy on cardiac sympathetic function in patients with chronic kidney disease 
has not yet been completely elucidated. The aim of this study was to evaluate the impact of renal replacement therapy on the 
activity of cardiac sympathetic nervous system.
MATERIAL AND METHODS: Thirty-four patients with chronic kidney disease were studied: 14 patients (6 men, mean age 48 ± 11 
years) were receiving peritoneal dialysis (PD) and 20 patients (20 men, mean age 52 ± 10 years) were receiving haemodialysis 
(HD). Patients with diabetes and heart failure were excluded from the study. All patients underwent resting gated myocardial 
perfusion and 123I-mIBG myocardial scintigraphy from which early and late heart to mediastinum ratios (HRM) and myocardial 
washout rate (WR) values were calculated.
RESULTS: PD and HD patients did not differ with respect to left ventricular ejection fraction (52 ± 9% vs. 57 ± 7%) and summed 
rest score (3.8 ± 2.4 vs. 3.5 ± 0.3). Similarly, early (1.89 ± 0.23 vs. 1.87 ± 0.27) and late (1.76 ± 0.47 vs. 1.74 ± 0.25) HMR, 
and washout rate (35.5 ± 15.8% vs. 31.3 ± 9.4%) were not significantly different between the two groups of patients.
CONCLUSIONS: These results suggest that the applied method of renal replacement therapy has no significant influence on 
global activity of cardiac sympathetic nervous system.
KEY words: cardiac sympathetic activity, 123I-mIBG cardiac scintigraphy, renal replacement therapy, myocardial 
perfusion study 
Nuclear Med Rev 2014; 17, 2: 75–82
Background
123I-meta-iodo-benzyl-guanidine (123I-mIBG) is a structural ana-
logue of the false neurotransmitter guanethidine, which is mainly 
taken up by the neuronal-specific uptake-1 into sympathetic nerve 
terminals. In negligible amount 123I-mIBG is carried by a non-specific 
uptake-2 into non neuronal cells, probably as a result of the pas-
sive diffusion. In neuronal uptake-1, 123I-mIBG is stored in the 
post-ganglionic, presynaptic endings of sympathetic neuron vesi-
cles and released via exocytosis by the same mechanism as nor-
epinephrine [1–6]. Therefore, the degree of the 123I-mIBG heart 
uptake reflects the presynaptic tone of the cardiac sympathetic 
nervous system (CSNS) [1–5]. This direct, non-invasive evaluation 
of CSNS is widely described [1–7]. The usefulness of this method 
is underscored in cardiac autonomic neuropathy, especially in 
diabetes mellitus (DM) [8–10], cardiac amyloidosis [11], ventricular 
arrhythmias, cardiomyopathy and heart failure [12–15]. 123I-mIBG 
cardiac scintigraphy is also used for the evaluation of the effec-
tiveness of specific treatments, e.g.: beta-blockers therapy [16], 
post-biventricular pacing [17], cardiac transplantation [18–20], 
and in assessing the impact of renal transplantation on the cardiac 
adrenergic system [21], as well in assessing the degree of local 
cardiac damage caused by myocarditis [22]. 
The development of chronic kidney disease (CKD) is closely 
related to increased activation of the sympathetic nervous system 
[23], which has been suggested as an important mechanism in 
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the cardiovascular events [24]. This is particularly important in Central 
Europe, where the number of patients treated with replacement renal 
therapy (RRT) has doubled every decade since 1980 [25]. What is more, 
in countries with low renal transplantation rate, a steady increasing 
amount of complications associated with RRT has been observed. 
This unfortunately increases the likelihood of sudden cardiac death 
(SCD) [26–28], which is the main cause of death in haemodialy-
sis patients [29, 30]. Moreover, the incidence of cardiac arrest is 100 
times higher in the dialysis population than in the general population [31]. 
The intermittent nature of HD and the electrolyte changes, which 
happen usually during haemodialysis sessions, activates sympa-
thetic nervous system [32]. On the contrary, in peritoneal dialy-
sis patients, especially in the commonly used continuous ambula-
tory peritoneal dialysis (CAPD) and continuous cycling peritoneal 
dialysis (CCPD), the activation of sympathetic nervous system by 
the prior-mentioned factors seems not to be so extensive. However, 
to the best of our knowledge, little or no work has been done to 
show the effect of applied PD on the function of CSNS as measured 
by 123I-mIBG myocardial uptake. Therefore, we decided to evaluate 
the impact of renal replacement therapy on the activity of cardiac 
sympathetic nervous system.
Material and methods
Patients
We studied a population of thirty-four patients in end stage 
renal disease (ESRD), who were receiving two different types of 
RRT: peritoneal dialysis (PD) and haemodialysis (HD).
The PD group consisted of fourteen patients (F/M: 8/6) aged 
29–70 years (mean 47.93 ± 11.43 years of age) receiving peritoneal 
dialysis (mean time 31.07 ± 24.33 months). Hypertension was treated 
in nine patients, for 9 to 100 months (mean 54.6 ± 38.23); the mean 
body mass index (BMI) came to 26.14 ± 4.4 1kg/m2 (Table 1). Pa-
tients received either peritoneal dialysis: CAPD (seven patients) or 
CCAPD (seven patients). The causes of ESRD were assessed as fol-
lows: glomerulonephritis (five patients), hypertension nephropathy 
(four patients), adult dominant polycystic kidney disease (one patient), 
chronic pyelonephritis (three patients) and obstructive nephropathy 
(one patient). None of these patients had peritonitis within 30 days be-
fore examination, nor did they show signs of any other inflammatory 
process. The imaging procedures were performed in all patients after 
the drainage of their peritoneal cavities (empty abdomen).
The HD group consisted of twenty patients (males; aged 
34–67; averaging 51.6 ± 10.03 years of age), who were haemo-
dialysed for 3 to 132 months (a mean 56.20 ± 47.43 months). In 
this group, hypertension was treated in seventeen patients for 
3 to 120 months (mean 50.4 ± 47.43 months); BMI came to 
24.83 ± 3.19 kg/m2 (Table 1). What is more, the underlying cause 
of renal failure was found to be chronic glomerulonephritis in fifteen 
of these patients, and miscellaneous in five patients. 
Exclusion criteria
Patients were excluded from this study if they had any of follow-
ings disorders: diabetes mellitus, amyloidosis, Parkinson’s disease, 
degenerative cerebral disease, past cerebral stroke, impaired 
thyroid function, neoplastic conditions, inflammations of connective 
Table 1. Results achieved in PD and HD groups
Group PD Group HD U-Mann-
Whitney test
N Mean SD N Mean SD Z p
Age (years) 14 47.9 11.43 20 51.6 10.93 –0.78 0.431
DD (months) 14 31.1 24.33 20 54.35 40.75 –1.73 0.083
HA (months) 14 0.9 0.32 20 50.4 47.43 –3.12 0.002*
BMI [kg/m2] 14 26,1 4,41 20 24.54 3.43 0.45 0.649
Ca2+ [mg/dl] 14 9.2 0.75 20 8.77 0.35 1.52 0.127
PO4
3- [mg/dl] 14 6.2 1.92 20 5.44 1.42 0.52 0.599
CaxP 14 54.8 17.97 20 46.26 12.62 1.29 0.195
PTH [mg/dl] 14 767.2 549.84 20 617 615.94 1.04 0.293
Hb [mg/dl] 14 11.3 0.95 20 11.22 1.17 0.11 0.912
A [mg/dl] 14 3.9 0.26 20 3.91 0.23 0.31 0.752
Kt/v 14 2.3 0.55 20 1.48 0.19 4.65 0.000*
LVEF (%) 14 52.8 7.71 20 57.5 7.19 –1.43 0.153
EDV [ml] 14 84.2 25.34 20 97.7 27.01 –1.01 0.312
ESV [ml] 14 40 16.47 20 41.2 17.61 0.13 0.895
SMS (score) 14 15.2 8.53 20 3.85 3.41 3.28 0.001*
eHMR 14 1.87 0.26 20 1.87 0.27 0.64 0.524
dHMR 14 1.72 0.32 20 1.74 0.25 0.00 1.000
WR (%) 14 38.2 18.64 20 31.38 9.49 0.55 0.582
SRS (score) 14 3.8 2.44 20 0.35 0.59 3.23 0.001*
DD — dialysis duration; HA — duration of hypertension; BMI — Body Mass Index; Ca — calcium; P — phosphate; CaxP — calcium-phosphate product; Hb — haemoglobin; A — serum 
albumin; Kt/V — marker of dialysis adequacy: K (clearance), t (time), V (volume); eHMR — early heart to mediastinum ratio; dHMR — delayed heart to mediastinum ratio; WR — washout rate; 
LVEF — left ventricular ejection fraction; EDV — end-diastole volume; ESV — end systole volume; SRS — summed rest score; SMS — summed motion score
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for 400 seconds. In addition, the 123I-mIBG uptake was evaluated 
visually and semi-quantitatively. The semi-quantitative assessment 
was comprised of a calculation of heart to mediastinum ratio (HMR) 
and myocardial washout rate (WR). This was done according to 
EANM proposal [33], as well as according to the previously described 
methods [34, 35]. To calculate HMR, two regions of interest (ROI) in the 
anterior planar image were determined (Figure 2). One was an irregular 
ROI of the heart (H), drawn over the entire outline of the heart (with its size 
depending on the patient’s heart); while the other was a rectangle ROI of 
the mediastinum (M) of 7 ¥ 7 pixels, selected from the central superior 
mediastinum sector. The HMR was calculated from early (eHMR) and 
delayed (dHMR) imaging as follows: HMR = mean count per pixel in H 
ROI/ mean count per pixel in M ROI. Furthermore, the myocardial WR 
was expressed as decreasing myocardial activity over time between the 
early and delayed imaging that was normalized to mediastinal activity in 
the following manner: WR = {early imaging (H-M) – delayed imaging 
(H-M)/early imaging (H-M)} ¥ 100%. 
A high observer reproducibility of planar HMR and SPECT de-
fect scores using 123I-mIBG cardiac imaging protocol in patients with 
heart failure has been recently reported [36].
It should be noted that the values of these indices depend 
on the calculation method [37] and the collimator type used [38]. 
According to the method applied in our study [33, 35], the normal 
ranges of global cardiac adrenergic function indices should be 
considered as follow: for eHMR: 1.89 ± 0.14; for dHMR: 1.93 ± 0.16 
[35]; and for WR: 20% ± 10% [39]. All calculations were done by 
way of the use of the same methods, independently by two expe-
rienced, “blinded” nuclear medical physicists. 
tissues, severe infections, dialysis-induced hypotension, relevant 
cardiovascular disease, left ventricular ejection fraction (< 50%), 
myocardial infarction, implanted pace maker or cardioverter/defibril-
lator, heart block (> 1st degree).
Anti-hypertensive medications, such as angiotensin converting en-
zyme inhibitors (ACEI) and angiotensin receptor blockers (ARB), in the 
patients with hypertension, were not withdrawn before 123I-mIBG scin-
tigraphy as suggested by Flotas et al. [33]. However, other drugs that 
might affect cardiac sympathetic system function were eliminated.
Ethics
Each of the patients signed an informed consent. The study 
protocol and informed consent forms were approved by the 
ethics committee of The Bioethical Council, Medical University of 
Lublin, Poland. 
All patients underwent both rest myocardial perfusion study and 
123I-mIBG myocardial scintigraphy. The tests were well tolerated by 
all of the patient.
Myocardial perfusion imaging
Myocardial perfusion gated single photon emission computed 
tomography (GSPECT) was performed in the rest condition, 60 min-
utes after an intravenous injection of 740 MBq of technetium-99m 
methoxy-isobutyl-isonitrile (Tc-99m MIBI). GSPECT acquisition 
was performed on rotating, double-head, large field of view 
gamma camera Varicam (Elscint, Haifa, Israel) or Symbia T16 
SPECT/CT hybrid gamma camera (Siemens, Erlangen, Germany), 
both equipped with low-energy, high-resolution collimators. A 20% 
analyser window was set symmetrically at 140 keV. The data was col-
lected on a 64 ¥ 64 matrix through a 180° rotation at 3° intervals; 
60 projections (50 seconds/view) in total. Moreover, the heart cycle 
was divided into 8 sequences. To reconstruct these images, a But-
terworth filter, order 5 and cut-off frequency 0.3 cycle/pixel, was used. 
The series of reconstructed images were analysed qualitatively and 
semi-quantitatively by the software program Quantitative Perfusion 
SPECT (QPS, Cedars-Sinai Medical Centre — CSMC). Using QPS, 
the perfusion of left ventricular myocardium in 17-segments was as-
sessed automatically by comparing these to the norm as summed 
rest scores (SRS). In this respect, a value of SRS below a score 
of 3 was considered as a norm. In the use of Quantitative Gated 
SPECT (QGS, CSMC), the following parameters were assessed: 
left ventricular ejection fraction (LVEF), end-diastolic volume (EDV), 
end-systolic volume (ESV), as well as summed motion score (SMS).
123I-mIBG myocardial scintigraphy
The activity of cardiac sympathetic nervous system was evaluated 
at rest condition, after an intravenous injection of 370 MBq 123I-mIBG. 
Following this, SPECT and anterior planar images of the chest were 
performed using the same gamma camera Varicam (Elscint, Haifa, 
Israel) or Symbia T16 SPECT/CT hybrid gamma camera (Siemens, 
Erlangen, Germany), in two stages: after 15 minutes (early imaging) and 
after 4 hours (delayed imaging). In all studies, a 15% energy window 
was set symmetrically at 159 keV. Moreover, low-energy, high-resolution 
collimators were used. Sixty (60) projections were collected (25s/projec-
tion) on a 64 ¥ 64 matrix in the SPECT studies, by way of a Butterworth 
reconstruction filter, order 5 and cut-off frequency 0.3 cycle/pixel (Figu - 
re 1). The anterior planar images were collected on a 128 ¥ 128 matrix 
Figure 1. 123I-mIBG SPECT, upper row of slices — 15 minutes post 
radiotracer injection, lower row — 4 hours post radiotracer injection
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observed in four patients (30%). Thus, the mean SRS value in PD 
group was mildly increased compared with the norm. The mean 
values of the global parameters of the left ventricle function, like: 
LVEF, EDV, ESV were within the normal range (Table 1). 
Visual analysis of 123I-mIBG SPECT revealed homogenous distri-
bution of the tracer within the myocardium in most of the patients (12 
of the 14 patients from PD group). In rest of the patients the evalua-
tion of the inferior wall of the left ventricle was problematical because 
of high activity within the abdominal cavity (Figure 3). 
The results of the semi-quantitative evaluation of the planar123I-mIBG 
myocardial scintigraphy are as follows: eHMR = 1.89 ± 0.23 (ranging 
from 1.25 to 2.15) and dHMR = 1.76±0.47 (ranging from 1.07 to 2.87); 
mean WR = 35.54±15.89% (ranging from 20.25 to 78.54%) (Table 2, 
Figure 4). In 2/14 of these PD patients, all CSNS indices were abnormal. 
Haemodialysis group
In the myocardial perfusion GSPECT study, the normal rest 
perfusion scans were found in 10/20 (50%) of the HD patients, 
while single area perfusion defects were seen in the remaining 
Figure 3. Poor quality of the 123I-mIBG SPECT, low uptake in inferior 
wall of left ventricle
Figure 2. I-123 mIBG planar AP projection of the thorax. Examples of 
the heart (H) and mediastinum (M) ROIs
Table 2. The indices of the global CSNS function in PD patients. Red boxes — abnormal values, orange boxes — normal values
No eHMR dHMR WR RRT
1 1.63 1.33 56.25 PD
2 2.02 1.87 23.26 PD
3 1.99 2.06 21.00 PD
4 1.90 1.78 25.55 PD
5 1.99 1.88 30.52 PD
6 2.03 2.08 19.26 PD
7 1.25 1.07 78.41 PD
8 2.07 1.93 38.97 PD
9 2.07 1.70 44.32 PD
10 1.79 1.50 45.26 PD
11 1.77 1.59 36.00 PD
12 1.95 1.63 44.00 PD
13 1.8 1.78 22.00 PD
14 2.15 2.11 24.00 PD
Statistical analysis
All values derived in this study are shown as mean value ± stan-
dard deviation (SD). The differences between parameters were 
estimated by employing the Mann-Whitney U test, while statistical sig-
nificance was defined as being p ≤ 0.05. All statistical analyses were 
performed using STATISTICA 6.0 (Stat Soft, Poland).
Results
Peritoneal dialysis group
The myocardial perfusion evaluated by GSPECT shows that 
normal rest myocardial perfusion was present only in three out of 
the fourteen patients (20%), while a single perfusion defect were 
found in seven patients (50%), and double perfusion defects were 
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10/20 patients (50%), so summed rest scores (SRS) were slightly 
increased compared with norm (Table 1). The mean values of the 
indices of the left ventricle function were in a normal range. 
Normal distribution of 123I-mIBG in SPECT study in the HD group 
was detected only in one patient, whereas in other cases, the exami-
nation reviled defects of radioisotope accumulation, mainly in the 
region of the posterior and postero-lateral walls and the heart apex. 
In assessment of the planar 123I-mIBG myocardial scintigraphy, 
the indices of global cardiac sympathetic nervous system function 
are as follows: mean value of eHMR = 1.87 ± 0.27 (ranging from 
1.46 to 2.30); mean value of dHMR = 1.74 ± 0.25 (ranging from 
1.31 to 2.24) and the mean value of WR = 31.38 ± 9.49 % (rang-
ing 17.42 to 44.92) (Table 3). In 5/20 of the HD patients, all CSNS 
indices were abnormal (Table 3, Figure 5).
Peritoneal dialysis group vs. haemodialysis group
In a comparison of the achieved results of the studied groups, 
four significant differences were found: two of these were related to 
clinical aspects and the other two concerned myocardial perfusion 
assessment (Table 1). With regards to clinical information, hyperten-
sion was treated for a longer period of time in the HD patients in 
comparison to the PD group, and the dialysis adequacy ratios Kt/V 
were better in the HD group, compared with those of the PD pa-
tients. Moreover, rest myocardial perfusion scores (SRS) and motion 
Figure 4. Global adrenergic indices in PD patient: eHMR = 1.99; dHMR = 1.88; WR = 28.67%
Table 3. The indices of the global CSNS function in HD patients. Red boxes — abnormal values, orange boxes — normal values
No eHMR dHMR WR RRT
1 2.44 2.24 33.86 HD
2 1.84 1.72 29.56 HD
3 1.87 1.62 41.85 HD
4 1.54 1.50 30.94 HD
5 2.05 1.97 27.25 HD
6 2.30 1.73 20.38 HD
7 1.93 1.89 22.47 HD
8 1.87 1.89 17.42 HD
9 2.15 2.12 21.75 HD
10 1.81 1.67 33.43 HD
11 1.46 1.42 48.8 HD
12 1.80 1.80 17.63 HD
13 1.82 1.63 43.83 HD
14 1.86 1.90 22.8 HD
15 1.76 1.60 34.66 HD
16 1.98 1.89 23.87 HD
17 1.54 1.39 36.83 HD
18 1.65 1.54 38.9 HD
19 2.23 2.04 36.5 HD
20 1.46 1.31 44.92 HD
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scores (SMS) were increased in the PD patients (which was confirmed 
in a visual analysis). However, there were no statistically significant 
differences between parameters of the global left ventricle function 
(LVEF, EDV, ESV), nor significant differences among the global cardiac 
sympathetic nervous system activity indices (eHMR, dHMR, WR). 
Discussion
Despite the taken efforts to reduce typical cardiovascular risk, 
the cardiovascular mortality rates are still elevated in dialysis pa-
tients [40, 41]. Although the nature of peritoneal dialysis and hae-
modialysis are basically different, the cardiovascular outcomes of 
patients undergoing these methods of RRT are comparable [42]. 
However, one of the most important risk factors of SCD — myocardi-
al stunning — is substantially lower in PD patients compared to HD 
patients [43]. Moreover, hemodynamic instability is associated with 
HD treatment rather than PD treatment. Yet, Jaar et al. concluded 
that mortality risk depends on dialysis type, and is significantly 
higher in PD patients. Moreover, it becomes more prominent in the 
second year of dialysis [44]. Due to the equivocal statements, we 
decided to investigate the differences in myocardial perfusion, glob-
al left ventricular function and cardiac sympathetic nervous system 
activation between HD and PD patients. Patients with accelerating 
myocardial ischaemia factors, like diabetes and dialysis-induced 
hypotension were excluded from this study [40, 43, 45].
Based on the clinical information, there were only two statisti-
cally significant differences between the studied groups. The first 
one was that the mean Kt/V index was higher (p = 0.000) in the PD 
patients, probably due to the residual diuresis that was preserved in 
this patients. And the second difference was that in the HD group 
hypertension was treated longer than in the PD patients (p = 0.002).
Patients with CKD have highly elevated cardiovascular mor-
bidity and mortality when compared to the general population. 
Hypertension and atherosclerosis are major risk factors of exten-
sive morbidity and mortality in those patients. Beyond traditional 
atherosclerosis accelerating factors like: diabetes, hypertension, 
obesity, dyslipidaemia, smoking, uraemia induced endothelial dys-
function and production of pro-inflammatory cytokines [46], there 
is also an increased activation of the sympathetic nervous system. 
Cardiovascular complications lead to death in 45–50% of all pa-
tients receiving dialysis, while 25% of the deaths in this group of 
patients were associated with CAD [46]. In respect to this situation, 
myocardial perfusion SPECT stress/rest study could be an excellent 
tool in predicting both cardiac events and the risk of SCD stratifica-
tion in ESRD patients [47, 48]. However, most of our patients had 
a low exercise tolerance, thus, the myocardial perfusion SPECT 
was conducted only at a rest. Pharmacologic stress test was also 
a problem in our patients due to a risk of hypertension instability. 
There was also a concern that these patients would not develop 
submaximal heart rate. Thus, test results could have been unreli-
able and incomparable, yet, in both groups, myocardial perfusion 
SPECT revealed normal to mild perfusion defects. 
In present study the mean value of SRS was significantly higher 
in the PD than in the HD patients (p = 0.001). Moreover, regional 
motion abnormalities (SMS) were more extensive in the PD group 
compared to HD group (p = 0.001). Overall, these findings coexist 
with normal global left ventricular function. 
As it has been mentioned before, the development of CKD 
is strictly related to the increased activation of the sympathetic 
nervous system. Kidney injury acts as a trigger mechanism of 
activation of SNS and renin-angiotensin system (RAS) [49, 50]. 
Cardiac sympathetic stimulation has chronotropic (increase in 
heart rate), inotropic (increase in contractile force), dromotropic 
(elevated atrioventricular conduction) and bathmotropic (increase 
in excitability) effects. Sympathetic activation also causes a rise 
in peripheral vascular resistance, sodium and water retention and 
activation of RAS [2, 51, 52]. The consequences of sustained sym-
pathetic nerve activation are the acceleration of hypertension and 
heart failure. In this respect, cardiac sympathetic nervous system 
hyperactivity can be diagnosed in all stages of CKD [23, 24, 26–28]. 
The distribution of the regional function of CSNS is evaluated visually 
by 123I-mIBG SPECT. 123I-mIBG SPECT studies are however often 
problematic due to high accumulation of the tracer in the lung, liver 
and relatively low uptake of 123I-mIBG in the heart, which occurs in 
a few cases. Moreover, the heterogeneous distribution of 123I-mIBG 
in the heart could portray a physiologic inhomogeneous function 
of sympathetic and parasympathetic innervations, which could be 
a source of misinterpretation. Furthermore, low inferior wall uptake of 
123I-mIBG (Figure 3), which was reported mostly in our HD patients, 
may predominantly result from innervations in this part of the heart 
Figure 5. Global adrenergic indices in HD patient: eHMR = 1.99; dHMR = 2.06; WR = 22.37%
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by parasympathetic fibres. In addition, the low uptake in the apex 
could be partially due to volume effect and imbalance between 
sympathetic and parasympathetic nerves [10, 37, 53].
The CSNS activation can be assessed directly by a semi-quan-
titative evaluation of 123I-mIBG myocardial uptake by the means of 
calculation of global cardiac adrenergic function indices, such as: 
eHMR, dHMR and WR. In our opinion this approach is more reliable 
than visual assessment of SPECT slices. The early HMR portrays the 
density of the cardiac presynaptic adrenergic nerves terminals, 
whereas late HMR reflects sympathetic neuronal function from 
uptake through storage and then to neurotransmitter release, 
especially NE [2, 5, 37]. Thus, decreasing myocardial uptake of 
123I-mIBG and increasing radiotracer myocardial washout rate are 
considered as being poor prognostic factors [1, 4, 6–8, 14] and re-
veal a high risk of cardiac death [54]. As our results show, the mean 
values of eHMR and dHMR in both studied groups were lower than 
normal values [37], whereas the mean values of WR were slightly 
increased compared to the norm [39], especially in the PD groups. 
Furthermore, our work confirmed that sympathetic nervous system 
hyperactivity happened even in low-risk patients and can appear 
earlier than global dysfunction of the left ventricle, which was also 
suggested previously [5, 55].
Dialysed patients are extremely burdened with the factors aris-
ing from chronic kidney disease. The dysfunction of the one factor 
in the cardio-renal axis involves abnormalities in the others [28]. 
Thus, efforts are made to minimize the negative effects of RRT. In 
our study, two different modalities of RRT were compared. However, 
the assessment of the regional distribution of sympathetic activity 
by use of 123I-mIBG SPECT was at times problematic to assess but 
the global indices of CSNS activation were similar in both the PD 
and HD groups. Hence, it can be said that the both methods of 
dialysis are comparable in the aspect of CSNS activation.
Conclusion
There are no significant differences between peritoneal and 
haemodialysed patients with regard to the influence of the ap-
plied method of RRT on global adrenergic activity, assessed by 
myocardial 123I-mIBG scintigraphy.
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